Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

  • Technology appraisal guidance
  • TA1043
  • Published: 
Download guidance (PDF)

2 Information about osimertinib

Marketing authorisation indication

2.1

Osimertinib (Tagrisso, AstraZeneca) is indicated for 'adjuvant treatment following complete tumour resection in adults with stage IB to IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations'.

Dosage in the marketing authorisation

Price

2.3

The list price for osimertinib is £5,770 per 30 pack of 80‑mg tablets (excluding VAT; BNF online accessed November 2024).

2.4

The company has a commercial arrangement. This makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence.